FISTULAE IN WOMEN TREATED WITH CHEMOTHERAPY WITH AND WITHOUT BEVACIZUMAB FOR PERSISTENT, RECURRENT OR METASTATIC CERVICAL CANCER IN GOG-240

被引：0
|
作者：
Willmott, L. J. [1 ]
Java, J. J. [2 ]
Monk, B. J. [3 ]
Shah, J. [4 ]
Husain, A. [4 ]
Tewari, K. S. [5 ]
机构：
[1] St Josephs Hosp, Phoenix, AZ USA
[2] Roswell Pk Canc Ctr, Stat Data Ctr, Buffalo, NY USA
[3] Creighton Univ, Phoenix, AZ USA
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] Univ Calif Irvine, Orange, CA USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2014年 / 24卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCSM-1194
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer
    McNamara, Blair
    Chang, Yifan
    Mutlu, Levent
    Harold, Justin
    Santin, Alessandro D.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (03) : 227 - 233
  • [2] Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients
    Godoy-Ortiz, A.
    Plata, Y.
    Alcaide, J.
    Galeote, A.
    Pajares, B.
    Saez, E.
    Alba, E.
    Sanchez-Munoz, A.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (07): : 922 - 927
  • [3] Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients
    A. Godoy-Ortiz
    Y. Plata
    J. Alcaide
    A. Galeote
    B. Pajares
    E. Saez
    E. Alba
    A. Sánchez-Muñoz
    [J]. Clinical and Translational Oncology, 2018, 20 : 922 - 927
  • [4] Bevacizumab plus chemotherapy versus combination chemotherapy only in metastatic, recurrent, and persistent cervical cancer
    Choi, H.
    Kim, B. G.
    Lee, Y. Y.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 154 : 275 - 275
  • [5] Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer
    Choi, Hyun-Jin
    Lee, Yoo-Young
    Choi, Chel Hun
    Kim, Tae-Joong
    Lee, Jeong-Won
    Bae, Ji Hye
    Bae, Duk-Soo
    Kim, Byoung-Gie
    [J]. CURRENT PROBLEMS IN CANCER, 2020, 44 (05)
  • [6] Fistula formation in cervical cancer patients treated with bevacizumab: Pharmacovigilance after GOG 240
    Huepenbecker, S. P.
    Lange, S. S.
    Chin, R. I.
    Wan, L.
    Markovina, S.
    Fuh, K. C.
    Hagemann, A. R.
    Kuroki, L. M.
    Thaker, P. H.
    Powell, M. A.
    Mutch, D. G.
    McCourt, C. K.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 154 : 144 - 145
  • [7] Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study
    Tewari, Krishnansu S.
    Sill, Michael W.
    Monk, Bradley J.
    Penson, Richard T.
    Long, Harry J., III
    Poveda, Andres
    Landrum, Lisa M.
    Leitao, Mario M.
    Brown, Jubilee
    Reid, Thomas J. A.
    Michael, Helen E.
    Moore, David H.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (24) : 5480 - 5487
  • [8] Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer The BC Cancer Experience
    Tinker, Anna V.
    Fiorino, Leathia
    O'Dwyer, Helena
    Kumar, Aalok
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (08) : 1592 - 1599
  • [9] Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer
    Eskander, Ramez N.
    Tewari, Krishnansu S.
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2014, 26 (04) : 314 - 321
  • [10] IMPACT OF THROMBOCYTOSIS IN WOMEN WITH OVARIAN CANCER TREATED WITH AND WITHOUT BEVACIZUMAB ON GOG 218
    Randall, L. M.
    Java, J.
    Bookman, M.
    Fleming, G.
    Monk, B. J.
    Walker, J.
    Homesley, H.
    Fowler, J.
    Greer, B.
    Burger, R. A.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 521 - 522
12345